Michael Gladstone
Director/Board Member chez THIRD HARMONIC BIO, INC.
Fortune : - $ au 31/03/2024
Profil
Michael Gladstone is a partner and focuses on building new therapeutics companies.
Michael is a co-founder and board member of Diagonal Therapeutics and Third Harmonic Bio (NASDAQ: THRD), and a board member of Aiolos Bio, Day One Biopharmaceuticals (NASDAQ: DAWN), and Pheon Therapeutics.
He is also a board observer for IFM Therapeutics LLC and Obsidian Therapeutics.
Michael was previously a board director for Versanis Bio (acquired by Lilly), and a board observer for Akero (NASDAQ: AKRO), AvroBio (NASDAQ: AVRO), Delinia (acquired by Celgene), Replimune (NASDAQ: REPL), and Xilio Therapeutics (NASDAQ: XLO).
Michael was a member of the founding teams of several Atlas-originated companies, including Padlock Therapeutics (acquired by BMS), Surface Oncology (NASDAQ: SURF), and IFM Therapeutics Inc. (acquired by BMS; and its spinout IFM Tre acquired by Novartis).
Prior to joining Atlas in 2012, Michael worked at L.E.K.
Consulting, where he focused on business development and corporate strategy for biopharma clients.
Previously, Michael worked in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center where he led research on HIV vaccines with Harvard Medical School Professor Norman Letvin.
Michael received an AB in biochemical sciences with highest honors from Harvard College, where he graduated magna cum laude and was awarded the Harvard College Scholarship and Herchel Smith Undergraduate Research Fellowship.
In his spare time, he enjoys spending time with his family, reading, and playing basketball enthusiastically but with rapidly declining effectiveness.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
15/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 | |
THIRD HARMONIC BIO, INC.
-.--% | 06/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Michael Gladstone
Sociétés | Poste | Début |
---|---|---|
DAY ONE BIOPHARMACEUTICALS, INC. | Director/Board Member | 01/12/2019 |
THIRD HARMONIC BIO, INC. | Director/Board Member | 01/04/2019 |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01/05/2015 |
Atlas Venture Life Science Advisors LLC
Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01/05/2015 |
Pheon Therapeutics Ltd.
Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Director/Board Member | 14/03/2022 |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The private company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Director/Board Member | - |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Director/Board Member | - |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Diagonal Therapeutics, Inc.
Diagonal Therapeutics, Inc. BiotechnologyHealth Technology Diagonal Therapeutics, Inc. is a biotechnology company located in the US that develops drugs for oncology, immunology, and rare diseases. | Director/Board Member | - |
Anciens postes connus de Michael Gladstone
Sociétés | Poste | Fin |
---|---|---|
░░░ ░░░░░░░░░ ░░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
░░░ ░░░░ ░░░░ | ░░░░░░░ | - |
Formation de Michael Gladstone
Harvard College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 6 |
---|---|
SPERO THERAPEUTICS, INC. | Health Technology |
REPLIMUNE GROUP, INC. | Health Technology |
AVROBIO, INC. | Health Technology |
AKERO THERAPEUTICS, INC. | Health Technology |
THIRD HARMONIC BIO, INC. | Health Technology |
DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 15 |
---|---|
The Lek/Alcar Consulting Group, Inc.
The Lek/Alcar Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Lek/Alcar Consulting Group, Inc. provides business strategy consulting services. It offers strategy, finance, marketing and sales, operations, and transaction services including business unit strategy, brand management, pricing, alliances and joint ventures, product development, corporate transformation, and operations design. It serves the defense, energy, health, building and construction, aerospace, media, retail, and telecommunications industries. The company was founded by Andrew Kutter in 1983 and is headquartered in Boston, MA. | Commercial Services |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Beth Israel Deaconess Medical Center, Inc.
Beth Israel Deaconess Medical Center, Inc. Hospital/Nursing ManagementHealth Services Beth Israel Deaconess Medical Center provides medical services. It offers patient care, biomedical research, teaching, and community services. It also provides organ transplantation, breast cancer care, and cardiac surgery services. The company was founded in 1896 and is headquartered in Boston, MA. | Health Services |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Life Science Advisors LLC
Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts. | Finance |
IFM Therapeutics LLC
IFM Therapeutics LLC Pharmaceuticals: MajorHealth Technology IFM Therapeutics LLC engages in the development and transformation of immunotherapy for patients with serious diseases. It focuses on developing small molecule drugs that target the innate immune system. The company was founded by Gary D. Glick, Luigi Franchi, Matthias Geyer, Eicke Latz, and Anthony W. Opipari, Jr. in 2015 and is headquartered in Boston, MA. | Health Technology |
Delinea, Inc. (United States)
Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Health Technology |
Indalo Therapeutics, Inc.
Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Health Technology |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Health Technology |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Health Technology |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The private company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Health Technology |
Xilio Therapeutics LLC
Xilio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The private company is based in Waltham, MA. The CEO of the company is René Russo. | Health Technology |
Pheon Therapeutics Ltd.
Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Health Technology |
Diagonal Therapeutics, Inc.
Diagonal Therapeutics, Inc. BiotechnologyHealth Technology Diagonal Therapeutics, Inc. is a biotechnology company located in the US that develops drugs for oncology, immunology, and rare diseases. | Health Technology |